Target intelligence / Profile preview

Dynein axonemal assembly factor 5 (DNAAF5)

Target
DNAAF5
Molecular classification
Other (cytoplasmic assembly factor), HEAT repeat-containing family, Axonemal dynein assembly factor
01

Overview

Dynein axonemal assembly factor 5 (DNAAF5), previously known as HEATR2, is a cytoplasmic protein essential for the preassembly and stability of axonemal dynein arms, which are large multisubunit motor protein complexes attached to microtubules within the ciliary axoneme[1][3][4]. DNAAF5 contains characteristic HEAT repeats (α-helical domains) and acts as a scaffold or chaperone, facilitating the assembly of both inner (IDA) and outer (ODA) axonemal dynein arms before their transport into motile cilia[2][4]. Mutations in DNAAF5 disrupt this preassembly pathway, resulting in the absence or dysfunction of dynein arms within the cilium and leading to the genetic disorder primary ciliary dyskinesia (PCD), which is characterized by impaired mucociliary clearance, recurrent respiratory infections, and, in severe cases, laterality defects and hydrocephalus[1][2][3][4]. DNAAF5 is expressed only in cells with motile cilia and is not found in the assembled cilium; its critical role is restricted to the cytoplasmic phase of dynein arm complex maturation[2][4]. There are no current drugs targeting DNAAF5, and the molecular mechanisms are relevant primarily for genetic diagnosis and research into ciliopathies.

Other names
HEATR2CILD18HEAT repeat-containing protein 2HEAT repeat containing 2dynein assembly factor 5, axonemalFLJ20397FLJ31671FLJ39381FLJ25564
02

Mechanism of action

Not applicable (no drugs currently target DNAAF5 directly)

03

Biological functions

Axonemal dynein motor assemblyPreassembly or stability of inner and outer dynein arms (IDA/ODA)Cilium/flagellum motilityCytoplasmic chaperone scaffolding for motor protein complexes
04

Disease associations

Primary ciliary dyskinesia (PCD)Motile ciliopathiesHydrocephalus (in animal models)Respiratory disease (via ciliary dysfunction)
05

Safety considerations

No approved therapeutic targeting; challenges would include potential cytotoxicity due to loss of essential ciliary motility in multiple organ systems
06

Interacting drugs

None identified in current literature
07

Biomarkers

DNAAF5 mutations or protein deficiency as a diagnostic or genetic marker for primary ciliary dyskinesia

Beyond the preview

Go deeper on Dynein axonemal assembly factor 5 (DNAAF5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynein axonemal assembly factor 5 (DNAAF5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call